8-(2-amino-3-chloro-5-(1-methyl-1H-indazol-5-yl)pyridin-4-yl)-2,8-diazaspiro[4.5]decan-1-one manufacturers
- CCT-251921
-
- $87.00
-
2026-07-27
- CAS:1607837-31-9
- Purity: 99.07%
- Supply Ability: 10g
- CCT-251921
-
- $87.00
-
2026-07-14
- CAS:1607837-31-9
- Purity: 99.07%
- Supply Ability: 10g
|
| | 8-(2-amino-3-chloro-5-(1-methyl-1H-indazol-5-yl)pyridin-4-yl)-2,8-diazaspiro[4.5]decan-1-one Basic information |
| Product Name: | 8-(2-amino-3-chloro-5-(1-methyl-1H-indazol-5-yl)pyridin-4-yl)-2,8-diazaspiro[4.5]decan-1-one | | Synonyms: | 8-(2-amino-3-chloro-5-(1-methyl-1H-indazol-5-yl)pyridin-4-yl)-2,8-diazaspiro[4.5]decan-1-one;CCT-251921;LM-3860,CCT251921;8-[2-amino-3-chloro-5-(1-methyl-1H-indazol-5-yl)-4-pyridinyl]-2,8-Diazaspiro[4.5]decan-1-one;CCT-251921;CCT 251921;8-[2-amino-3-chloro-5-(1-methylindazol-5-yl)pyridin-4-yl]-2,8-diazaspiro[4.5]decan-1-one;2,8-Diazaspiro[4.5]decan-1-one, 8-[2-amino-3-chloro-5-(1-methyl-1H-indazol-5-yl)-4-pyridinyl]-;CCT-251921,Cyclin dependent kinase,Inhibitor,CDK,CCT251921,CCT 251921,inhibit | | CAS: | 1607837-31-9 | | MF: | C21H23ClN6O | | MW: | 410.9 | | EINECS: | | | Product Categories: | | | Mol File: | 1607837-31-9.mol | ![8-(2-amino-3-chloro-5-(1-methyl-1H-indazol-5-yl)pyridin-4-yl)-2,8-diazaspiro[4.5]decan-1-one Structure](CAS/20180703/GIF/1607837-31-9.gif) |
| | 8-(2-amino-3-chloro-5-(1-methyl-1H-indazol-5-yl)pyridin-4-yl)-2,8-diazaspiro[4.5]decan-1-one Chemical Properties |
| Boiling point | 696.4±55.0 °C(Predicted) | | density | 1.51±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : ≥ 28 mg/mL (68.14 mM) | | pka | 15.81±0.20(Predicted) | | form | Solid | | color | White to off-white |
| | 8-(2-amino-3-chloro-5-(1-methyl-1H-indazol-5-yl)pyridin-4-yl)-2,8-diazaspiro[4.5]decan-1-one Usage And Synthesis |
| Description | CCT251921 is a potent, selective, and orally bioavailable small-molecule modulators of the mediator complex-associated kinases CDK8 and CDK19. (IC50 data: CDK8:=2.3 nM; CDK19 = 2.6 nM). CCT251921 showed the optimal compromise of in vitro biochemical, pharmacokinetic, and physicochemical properties and is suitable for progression to animal models of cancer. The Mediator complex-associated cyclin-dependent kinase CDK8 has been implicated in human disease, particularly in colorectal cancer where it has been reported as a putative oncogene. | | Uses | CCT-251921 is a potent, selective, and orally bioavailable CDK8 inhibitor with an IC50 of 2.3 nM. | | in vivo | CCT-251921 shows improved oral pharmacokinetics and pharmaceutical properties in order to facilitate further evaluation of CDK8/19 pharmacology and progression into preclinical efficacy and safety studies. In APC-mutant SW620 human colorectal carcinoma xenograft model, CCT-251921 treatment reduces mice tumor weight (54.2%) at day 15. The inhibition of STAT1SER727 phosphorylation is maintained for more than 6 h after the last dose[1]. | | IC 50 | CDK8: 2.3 nM (IC50); CDK19: 2.6 nM (IC50) | | References | [1] Mallinger A, et al. Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19. J Med Chem. 2016 Feb 11;59(3):1078-101. DOI:10.1021/acs.jmedchem.5b01685 |
| | 8-(2-amino-3-chloro-5-(1-methyl-1H-indazol-5-yl)pyridin-4-yl)-2,8-diazaspiro[4.5]decan-1-one Preparation Products And Raw materials |
|